Pulmonary Arterial Hypertension research hub
28 indexed studies · 12 currently recruiting
- active not recruitingPHASE3
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
This study looks at a new, higher dose of macitentan (75mg) for people with pulmonary arterial hypertension (PAH). Researchers want to see if this dose is better than the current 10mg dose at preventing serious health problems or death related to PAH.
United States · Argentina · Australia - recruitingPHASE3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This study is looking into the long-term safety and effectiveness of an inhaled medicine called seralutinib for adults with pulmonary arterial hypertension (PAH). Participants have already tried seralutinib in an earlier study and will continue to take it.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
This study is testing a new medication, HS235, for adults with Pulmonary Arterial Hypertension (PAH), a condition that affects blood pressure in the lungs. It aims to see if HS235 is safe, how it works in the body, and if it helps improve health when added to usual treatments.
United States · Spain · United Kingdom - recruitingPhase I/II
A study to learn how the study medicine called PF-07868489 is tolerated and acts in people with pulmonary arterial hypertension
This study is looking into a new medicine, PF-07868489, for pulmonary arterial hypertension (PAH). Researchers want to see if it's safe and how it works in people with this lung condition. It's an early-stage study to understand the medicine better.
United Kingdom · England · Scotland - active not recruitingPHASE2
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
This study is looking into a new treatment called sotatercept for pulmonary arterial hypertension (PAH). It's an extension of a previous study. The main aim is to see if sotatercept, given in doses based on weight groups, is safe and can be tolerated by people with PAH over a longer time.
United States · Argentina · Australia - recruiting
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
This study aims to see if a special scan can detect changes in the lungs of people with Pulmonary Arterial Hypertension (PAH). By comparing these scans to healthy people, we hope to find a new way to check if treatments for PAH are working.
United Kingdom - active not recruitingPHASE4
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
This study aims to improve treatment for a serious lung condition called Pulmonary Arterial Hypertension (PAH). Researchers are using tiny implanted devices and approved medications to see if personalised changes to treatment plans can be quickly and effectively monitored at home.
United Kingdom - recruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
United States · Argentina · Australia - recruiting
Myocardial Work Evaluation in Patients With PAH
This study looks at a new way to measure how well the right side of the heart works in people with high blood pressure in the lungs (PAH). This measurement, called 'myocardial work', might help doctors predict how PAH patients will do in the future.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (TROPOS-Study)
This study is testing a new medicine, cibotercept (also known as KER-012), for adults with pulmonary arterial hypertension (high blood pressure in the lungs). Researchers want to see if it's safe and helps improve lung blood vessel function when added to existing treatments.
Germany · Portugal · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
This study is testing a new inhaled powder medicine for a lung condition called pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients and if it's safe. It compares different strengths of the new medicine against a dummy powder.
Belgium · Italy · Spain - active not recruitingPHASE2
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
This study looks at the long-term effects of a drug called GB002 (seralutinib) for people with Pulmonary Arterial Hypertension (PAH). Participants have already been part of a previous GB002 study. It's an open-label study, meaning everyone knows they are receiving the drug.
United States · Australia · Czechia - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants
This study is testing a medicine called macitentan in healthy adults. It aims to see how different doses affect the body, especially how it clears a natural substance called endothelin-1 and impacts blood vessel health. It's an early-stage study to understand the drug better.
France - authorisedPhase II and Phase III (Integrated)
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
This study is looking into a new tablet medicine, IKT-001, for a serious lung condition called pulmonary arterial hypertension. It aims to see if the medicine is safe and helps people walk further and feel better.
Spain · Poland · Italy - authorisedHuman Pharmacology (Phase I)- Other
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
This study is looking into a new medicine for pulmonary arterial hypertension (PAH), a condition that affects blood vessels in the lungs. It aims to find a safe and effective dose of this new drug, called HS235, when added to usual treatments. The study will also see how the body handles the medicine.
Hungary · Spain · Poland - active not recruitingPHASE2, PHASE3
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
This study looks at the long-term safety of a new inhaled medicine, Treprostinil Palmitil (TPIP), for people with a lung condition called Pulmonary Arterial Hypertension (PAH). It's for those who have already tried TPIP in earlier studies.
United States · Argentina · Austria - recruitingPHASE2
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
This study is testing a new medication called APL-9796 for adults with high blood pressure in their lungs, known as pulmonary hypertension. We want to see if it's safe, tolerable, and if it helps improve their condition. It's an early-stage study.
United Kingdom - active not recruitingPHASE1, PHASE2
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
This study is testing a new medicine, PF-07868489, for a lung condition called Pulmonary Arterial Hypertension (PAH). Researchers want to see if it's safe and how it works in healthy people and those with PAH. It's an early-stage study to understand the medicine better.
United States · Australia · Belgium - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is testing a new inhaled medicine, saralutinib, for people with pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients walk further in six minutes and improves their health compared to a dummy inhaler.
Spain · Lithuania · Greece - recruitingNA
Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
This study looks at whether regular exercise, alongside usual medicines, improves fitness and wellbeing in people newly diagnosed with pulmonary hypertension. It also checks if extra support helps people keep exercising in the long run.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants
This study looks at a medicine called macitentan, which is used for a lung condition called pulmonary hypertension. Researchers want to see how different doses of this medicine affect healthy people, focusing on how their blood vessels work.
France - active not recruitingPHASE2
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
This study is testing a medicine called selexipag (Uptravi) in children aged 2 to 17 with a lung condition called pulmonary arterial hypertension (PAH). The main goal is to find the right starting dose for children so they receive a similar amount of medicine as adults.
United States · Belarus · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- Other
An Early Phase Study to Investigate the Safety and Efficacy of HS135 in Adult Patients With Pulmonary Arterial Hypertension (PAH)
This early study looks at a new medicine called HS135 for adults with a serious lung condition called pulmonary arterial hypertension (PAH). Researchers want to see if it's safe and how well it works to help patients feel better. It's one of the first times this medicine is being tested in people.
Hungary · Poland · Germany - recruitingPHASE2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
This study is looking at a new medicine called sotatercept for children aged 1 to 17 with a serious lung condition called pulmonary arterial hypertension (PAH). We want to see if it's safe and how the body handles it over 24 weeks, alongside their usual PAH treatments.
United States · Australia · Colombia - recruitingPHASE3
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This study looks into a new medicine, IKT-001, for adults in the UK with a specific type of high blood pressure in the lungs, called Pulmonary Arterial Hypertension (PAH). It compares IKT-001 with a dummy treatment (placebo) to see if it's safe and helps improve symptoms.
United States · Argentina · Australia - enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
United States · Argentina · Australia - recruitingNA
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
This study is testing a new device called a V-Wave Interatrial Shunt for people with severe pulmonary arterial hypertension (PAH). It aims to see if the device is safe, works as intended, and could help reduce problems with the right side of the heart.
United States · Canada · Mexico - recruitingPHASE4
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
This study compares two ways to treat high blood pressure in the lungs (PAH): a new combination of three medicines, including one given by injection, versus two oral medicines. It aims to find out which approach works better for patients with intermediate to high risk.
Austria · Czechia · France